Mecure Industries sees revenue surge 177% to N6.46bn

Mecure Industries Plc delivered a pointy rebound in profitability for the 12 months ended 31 December 2025, with revenue after tax rising 177 per cent to N6.46 bn in comparison with N2.33 bn, in line with its audited monetary statements.

Income for the pharmaceutical producer grew to N77.69bn in 2025, up from N46.03bn in 2024, representing a 69 per cent enhance year-on-year. The expansion in turnover was supported by improved gross sales efficiency throughout its product strains through the interval.

The corporate recorded robust income progress throughout all product classes in 2025 in contrast with 2024, underscoring broad-based growth in its portfolio. Income from the acute phase rose considerably to N42.57bn in 2025, up from N25.22bn in 2024, remaining the biggest contributor to complete turnover. The OTC class additionally delivered strong progress, growing to N17.31bn from N10.26bn within the prior 12 months.

Gross sales from dietary supplements climbed to N8.70bn, in contrast with N5.15bn in 2024, whereas income generated from persistent merchandise grew to N5.35bn from N3.17bn.

The Narcotics phase recorded N2.52bn in income, up from N1.49bn a 12 months earlier. Promotional gross sales likewise elevated to N1.24bn in contrast with N736.85m in 2024.

On the steadiness sheet, complete property rose to N81.96bn as of 31 December 2025, up from N54.84bn in 2024.

The Administrators suggest a dividend payout of 20 per cent of Earnings Per Share, amounting to N0.32 per share, in respect of the monetary efficiency for the 12 months ended 31 December 2025, topic to the approval of the shareholders (2024: N0.15 per share).

The audited outcomes level to a 12 months of stronger operational execution and margin growth for Mecure Industries, with income progress and price self-discipline combining to ship a marked enchancment in profitability and shareholder returns.